Dogwood Therapeutics Inc. announced positive interim results from its ongoing Phase 2b clinical trial evaluating Halneuron® in patients with chemotherapy-induced neuropathic pain (CINP). According to the company, an independent statistical review committee found that patients treated with Halneuron® showed separation from placebo in pain improvement assessments over the four-week study period. The interim analysis was based on data from 97 patients who had completed treatment. The company reported a study dropout rate of approximately 4.4%, which it noted is lower than rates typically observed with other FDA-approved chronic pain medications. Dogwood Therapeutics expects to present top-line results from the trial in the third quarter of 2026.